10,200 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Purchased by Sage Capital Advisors llc

Sage Capital Advisors llc purchased a new position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 10,200 shares of the biopharmaceutical company’s stock, valued at approximately $99,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Point72 Hong Kong Ltd bought a new position in Amicus Therapeutics in the 2nd quarter worth approximately $49,000. US Bancorp DE lifted its holdings in Amicus Therapeutics by 50.9% during the 2nd quarter. US Bancorp DE now owns 4,896 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 1,651 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Amicus Therapeutics during the 2nd quarter valued at about $215,000. Profund Advisors LLC boosted its position in Amicus Therapeutics by 12.5% in the second quarter. Profund Advisors LLC now owns 22,860 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 2,546 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in Amicus Therapeutics in the third quarter valued at about $240,000.

Several research firms have recently weighed in on FOLD. Cowen set a $31.00 price objective on shares of Amicus Therapeutics and gave the stock a “buy” rating in a report on Thursday, October 10th. ValuEngine upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, January 7th. BidaskClub downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 31st. Cantor Fitzgerald restated an “overweight” rating on shares of Amicus Therapeutics in a report on Thursday, October 17th. Finally, Zacks Investment Research upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 target price for the company in a research note on Monday, November 4th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Amicus Therapeutics has an average rating of “Buy” and an average price target of $17.96.

In related news, Director Margaret G. Mcglynn sold 20,000 shares of the firm’s stock in a transaction dated Thursday, January 9th. The stock was sold at an average price of $10.00, for a total value of $200,000.00. Following the transaction, the director now owns 42,064 shares in the company, valued at $420,640. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John F. Crowley sold 40,000 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $10.01, for a total value of $400,400.00. Following the completion of the transaction, the chief executive officer now owns 775,694 shares in the company, valued at approximately $7,764,696.94. The disclosure for this sale can be found here. In the last quarter, insiders sold 196,216 shares of company stock worth $1,912,331. 2.50% of the stock is owned by company insiders.

Shares of FOLD traded up $0.11 during mid-day trading on Thursday, hitting $10.50. 105,071 shares of the company traded hands, compared to its average volume of 3,047,240. The company has a current ratio of 6.20, a quick ratio of 6.10 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $2.65 billion, a price-to-earnings ratio of -7.92 and a beta of 1.55. The business has a 50-day moving average of $9.83 and a 200 day moving average of $10.00. Amicus Therapeutics, Inc. has a one year low of $7.11 and a one year high of $14.61.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Monday, November 11th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.08. Amicus Therapeutics had a negative net margin of 216.02% and a negative return on equity of 62.61%. The firm had revenue of $48.80 million during the quarter, compared to analysts’ expectations of $48.05 million. During the same quarter in the previous year, the company posted ($0.84) EPS. Amicus Therapeutics’s revenue was up 136.9% on a year-over-year basis. As a group, analysts anticipate that Amicus Therapeutics, Inc. will post -1.22 earnings per share for the current year.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Read More: How do investors use RSI to grade stocks?

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.